• Irwin Katsof resigned from the board on June 9, 2026, stepping down from its committees.
• William Conkling was appointed to the board, with a term running to the 2026 annual meeting.
• Conkling is expected to chair the audit committee, serve as audit committee financial expert, join the compensation committee.
• Conkling has been chief commercial officer at Protara Therapeutics since June 2025.
• He previously led Rafael Holdings as CEO, held senior commercialization roles at Immunomedics, spent more than 10 years at Novartis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IDT Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-020335), on June 11, 2026, and is solely responsible for the information contained therein.